六月 2026
- Home
- OBI Pharma
六月 2026的OBI Pharma市场份额分析
In 2014, OBI Pharma established the “Corporate Social Responsibility Practice Code” as a governance regulation to ensure internal adherence to environmental and social sustainability commitments and fulfill the information disclosure obligations of a publicly listed company. This code has been continuously updated to reflect changes in government regulations and the company’s evolving needs. In 2021, […]
OBI Pharma(包含公司地区分支机构)
查看更多网站流量和参与度信息- obipharma.com
OBI Pharma收入截至 六月 2026为 25M - 50M
OBI Pharma主要域名产生的收入
3 年中OBI Pharma主要域名的收入
OBI Pharma主要域名的收入
OBI Pharma热门域名的总访问量
了解OBI Pharma市场份额和潜在市场覆盖范围。
过去 3 个月的总访问量
子公司明细
OBI Pharma热门域名的平均访问时长
分析OBI Pharma参与度指标。
过去 3 个月的平均访问时长
子公司明细
OBI Pharma热门域名的平均页面浏览量
了解OBI Pharma如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。
过去 3 个月的平均页面浏览量
子公司明细
想要获取更深入的流量洞见?
过滤超过 2030 万家在线企业。发现流量激增的新潜在客户,开始或停止使用技术的新潜在客户,或者获得正面报道的新潜在客户。
OBI Pharma 的新闻与信号
借助 Similarweb 销售信号提醒,每当在目标受众之中出现新的机会或威胁时,您都会收到所识别出购买信号的每日更新。
新闻OBI Pharma, Inc. launches GlycOBIR glycan site-specific conjugation technology at 5th World ADC Summit South Korea.During the conference, OBI Pharma's Senior Director of ADC Key Technology, Huang Dengyi, introduced the application of GlycOBIR glycan site-specific conjugation technology in homogeneous ADC design and DAR regulation, and shared the 'plug-and-play' characteristic of the GlycOBI DUOR platform, which can precisely connect two different payloads to a single antibody to create a dual-drug ADC with multiple mechanisms of action.
六月 11, 2026阅读更多
新闻OBI Pharma, Inc. attended event AACR 2026 on Apr 15th '26.TAIPEI, TW / ACCESS Newswire / April 15, 2026 / OBI Pharma, Inc. (TPEx:4174.TWO) today announced its presence at AACR 2026, highlighted by ten poster presentations, showcasing the transformative potential of the GlycOBI(R) platform.
四月 15, 2026阅读更多
新闻OBI Pharma, Inc. partners with Nippon Fine Chemical Co..TAIPEI, Taiwan, March 07, 2025 (GLOBE NEWSWIRE) - Amaran Biotechnology Inc., a subsidiary of OBI Pharma specializing in Contract Development and Manufacturing Organization (CDMO) services for next-generation pharmaceuticals, announced today that it has signed a Memorandum of Understanding (MOU) with Nippon Fine Chemical Co., Ltd., and its Taiwan subsidiary, Zillion Fine Chemicals International Co., Ltd.
三月 7, 2025阅读更多
查看 OBI Pharma 的所有信号
让您的销售团队专注于最有希望的机会。通过分清机会的轻重缓急并在合适的时机介入,您可以优化工作并达成更多交易。
